A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Summary

A Randomized Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Timeline

Start

2020-08-17

Primary completion

2022-03-08

Completion

2022-03-08

Outcome

Missed primary endpoint

Stopped: “Lack of antiviral activity at the projected efficacious dose.”

release “ALG-010133 cannot meaningfully contribute to achieving functional cures in CHB” aligos.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ALG-010133	Unknown	—	Subcutaneous

Indications